P2Y12 inibitori

Safety and efficacy of different P2Y12 inhibitors in patients with acute coronary syndromes stratified by the PRAISE risk score: a multicentre study.

Aims: To establish the safety and efficacy of different dual antiplatelet therapy (DAPT) combinations in patients with acute coronary syndrome (ACS) according to their baseline ischaemic and bleeding risk estimated with a machine learning derived model [machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE) score].

LEGGI TUTTO »

Quick Survey 07

Tra le raccomandazioni delle “2020 ESC guidelines on non-ST-segment elevation acute coronary syndrome” la controindicazione (classe III) al pretrattamento con gli inibitori del recettore P2Y12 ha destato scalpore e critiche.

LEGGI TUTTO »
Cerca un articolo
Gli articoli più letti
Rubriche
Leggi i tuoi articoli salvati
La tua lista è vuota